{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:26:13Z","timestamp":1777879573012,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272845"],"award-info":[{"award-number":["82272845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023LZL001"],"award-info":[{"award-number":["ZR2023LZL001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023ZD26"],"award-info":[{"award-number":["ZR2023ZD26"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Collaborative Academic Innovation Project of Shandong Cancer Hospital","award":["ZF003"],"award-info":[{"award-number":["ZF003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10495-026-02332-z","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T09:33:43Z","timestamp":1774776823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DKK1 expression associates with tertiary lymphoid structure maturity in non-small cell lung cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Lin","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junxu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"3","key":"2332_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2332_CR2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-025-02243-6","volume":"10","author":"Q Huang","year":"2025","unstructured":"Huang Q, Li Y, Huang Y, Wu J, Bao W, Xue C et al (2025) Advances in molecular pathology and therapy of non-small cell lung cancer. Signal Transduct Target Ther 10(1):186","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2332_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD (2022) First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol 40(6):586\u2013597","journal-title":"J Clin Oncol"},{"issue":"14","key":"2332_CR4","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","volume":"383","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH et al (2020) Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 383(14):1328\u20131339","journal-title":"N Engl J Med"},{"issue":"6","key":"2332_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH (2019) Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 19(6):307\u2013325","journal-title":"Nat Rev Cancer"},{"issue":"6576","key":"2332_CR6","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher TN, Thommen DS (2022) Tertiary lymphoid structures in cancer. Science 375(6576):eabf9419","journal-title":"Science"},{"issue":"1","key":"2332_CR7","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.medj.2024.10.023","volume":"6","author":"F Peyraud","year":"2025","unstructured":"Peyraud F, Guegan JP, Vanhersecke L, Brunet M, Teyssonneau D, Palmieri LJ et al (2025) Tertiary lymphoid structures and cancer immunotherapy: from bench to bedside. Med 6(1):100546","journal-title":"Med"},{"issue":"7791","key":"2332_CR8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R et al (2020) B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549\u2013555","journal-title":"Nature"},{"issue":"7791","key":"2332_CR9","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S et al (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561\u2013565","journal-title":"Nature"},{"issue":"7791","key":"2332_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez F, de Reyni\u00e8s A, Keung EZ, Chen TW, Sun CM, Calderaro J et al (2020) B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791):556\u2013560","journal-title":"Nature"},{"issue":"8","key":"2332_CR11","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke L, Brunet M, Gu\u00e9gan JP, Rey C, Bougouin A, Cousin S et al (2021) Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat Cancer 2(8):794\u2013802","journal-title":"Nat Cancer"},{"issue":"10","key":"2332_CR12","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1136\/gutjnl-2022-328697","volume":"72","author":"GS Kinker","year":"2023","unstructured":"Kinker GS, Vitiello GAF, Diniz AB, Cabral-Piccin MP, Pereira PHB, Carvalho MLR et al (2023) Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas. Gut 72(10):1927\u20131941","journal-title":"Gut"},{"key":"2332_CR13","doi-asserted-by":"publisher","first-page":"1413067","DOI":"10.3389\/fimmu.2024.1413067","volume":"15","author":"X Bao","year":"2024","unstructured":"Bao X, Lin X, Xie M, Yao J, Song J, Ma X et al (2024) Mature tertiary lymphoid structures: important contributors to anti-tumor immune efficacy. Front Immunol 15:1413067","journal-title":"Front Immunol"},{"issue":"9","key":"2332_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41568-024-00728-0","volume":"24","author":"JL Teillaud","year":"2024","unstructured":"Teillaud JL, Houel A, Panouillot M, Riffard C, Dieu-Nosjean MC (2024) Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer 24(9):629\u2013646","journal-title":"Nat Rev Cancer"},{"key":"2332_CR15","doi-asserted-by":"publisher","first-page":"217491","DOI":"10.1016\/j.canlet.2025.217491","volume":"613","author":"X Cui","year":"2025","unstructured":"Cui X, Gu X, Li D, Wu P, Sun N, Zhang C, He J (2025) Tertiary lymphoid structures as a biomarker in immunotherapy and beyond: advancing towards clinical application. Cancer Lett 613:217491","journal-title":"Cancer Lett"},{"issue":"8","key":"2332_CR16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.ccell.2024.07.006","volume":"42","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu G, Zeng Q, Wu W, Lei K, Zhang C et al (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. Cancer Cell 42(8):1370\u201385e9","journal-title":"Cancer Cell"},{"issue":"2","key":"2332_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cell.2024.10.042","volume":"188","author":"L Onder","year":"2025","unstructured":"Onder L, Papadopoulou C, L\u00fctge A, Cheng HW, L\u00fctge M, Perez-Shibayama C et al (2025) Fibroblastic reticular cells generate protective intratumoral T cell environments in lung cancer. Cell 188(2):430\u2013446.e20","journal-title":"Cell"},{"issue":"1","key":"2332_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41389-024-00537-y","volume":"13","author":"CC Hsieh","year":"2024","unstructured":"Hsieh CC, Li TW, Li CC, Chen SH, Wei YL, Chiang NJ, Shen CH (2024) DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer. Oncogenesis 13(1):34","journal-title":"Oncogenesis"},{"key":"2332_CR19","doi-asserted-by":"publisher","first-page":"658097","DOI":"10.3389\/fimmu.2021.658097","volume":"12","author":"HY Chu","year":"2021","unstructured":"Chu HY, Chen Z, Wang L, Zhang ZK, Tan X, Liu S et al (2021) Dickkopf-1: a promising target for cancer immunotherapy. Front Immunol 12:658097","journal-title":"Front Immunol"},{"issue":"5","key":"2332_CR20","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1084\/jem.20150950","volume":"213","author":"L D\u2019Amico","year":"2016","unstructured":"D\u2019Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B et al (2016) Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer. J Exp Med 213(5):827\u2013840","journal-title":"J Exp Med"},{"issue":"3","key":"2332_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1200\/JCO.24.00410","volume":"43","author":"SJ Klempner","year":"2025","unstructured":"Klempner SJ, Sonbol MB, Wainberg ZA, Uronis HE, Chiu VK, Scott AJ et al (2025) DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy in advanced gastric or gastroesophageal junction adenocarcinoma: DisTinGuish. J Clin Oncol 43(3):339\u2013349","journal-title":"J Clin Oncol"},{"issue":"12","key":"2332_CR22","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1158\/2326-6066.CIR-22-0218","volume":"10","author":"T Shi","year":"2022","unstructured":"Shi T, Zhang Y, Wang Y, Song X, Wang H, Zhou X et al (2022) DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer. Cancer Immunol Res 10(12):1506\u20131524","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2332_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V et al (2023) Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat Genet 55(5):807\u2013819","journal-title":"Nat Genet"},{"issue":"12","key":"2332_CR24","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L et al (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med 25(12):1916\u20131927","journal-title":"Nat Med"},{"issue":"7693","key":"2332_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y et al (2018) TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"issue":"9","key":"2332_CR26","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.7150\/ijbs.113737","volume":"21","author":"S Zhou","year":"2025","unstructured":"Zhou S, Ye S, Chen L, Ge Q, Lu J, Anwaier A et al (2025) Interferon regulatory factor 4 recruits immature B cells to signal tertiary lymphoid structure immaturity and progression of clear cell renal cell carcinoma. Int J Biol Sci 21(9):3827\u20133851","journal-title":"Int J Biol Sci"},{"key":"2332_CR27","doi-asserted-by":"crossref","unstructured":"Jiao M, Guo Y, Zhang H, Wen H, Chen P, Wang Z et al (2025) ACAT1 regulates tertiary lymphoid structures and correlates with immunotherapy response in non-small cell lung cancer. J Clin Invest 135(7)","DOI":"10.1172\/JCI181517"},{"key":"2332_CR28","doi-asserted-by":"crossref","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362(6411)","DOI":"10.1126\/science.aar3593"},{"key":"2332_CR29","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ et al (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150","journal-title":"Nat Commun"},{"issue":"8","key":"2332_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2332_CR31","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jaci.2017.12.998","volume":"142","author":"HW Cheng","year":"2018","unstructured":"Cheng HW, Onder L, Cupovic J, Boesch M, Novkovic M, Pikor N et al (2018) CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses. J Allergy Clin Immunol 142(4):1257\u201371e4","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"2332_CR32","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ncb3613","volume":"19","author":"X Zhuang","year":"2017","unstructured":"Zhuang X, Zhang H, Li X, Li X, Cong M, Peng F et al (2017) Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol 19(10):1274\u20131285","journal-title":"Nat Cell Biol"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02332-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02332-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:47:31Z","timestamp":1777592851000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02332-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2332"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02332-z","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study met the standards approved by the Ethics Committee of Shandong Cancer Hospital. The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was waived because of the retrospective design.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"116"}}